[May 17, 2017] |
|
Viamet Data for VT-1161 and VT-1598 to be Presented at The American Society for Microbiology's ASM Microbe 2017 Conference
Viamet
Pharmaceuticals, Inc. today announced that data from its VT-1161 and
VT-1598 therapeutic programs will be presented in multiple posters at
The American Society for Microbiology's ASM (News - Alert) Microbe 2017 Conference,
being held June 1-5 at the Ernest N. Morial Convention Center in New
Orleans, Louisiana. The posters will include the first public
presentation of Viamet's successful Phase 2b results for VT-1161 in the
treatment of recurrent vulvovaginal candidiasis (RVVC), and highlight
the potent activity of Viamet's antifungal candidates against a breadth
of endemic and multi-drug resistant fungal species.
"Current antifungal therapies are limited by safety concerns, drug
interactions and increasing reports of fungal resistance to treatment,"
said Robert Schotzinger, M.D., Ph.D., President and CEO of Viamet. "Our
objective in building Viamet's extensive antifungal pipeline has been to
design broad-spectrum agents that have the potential to provide superior
efficacy and safety to meet the needs of patients and clinicians across
a wide range of fungal diseases. Viamet's poster presentations will
showcase two of our advanced antifungal programs and include clinical
data demonstrating the robust efficacy and safety of VT-1161 in the
treatment of RVVC as well as preclinical data for VT-1598 demonstrating
promising activity against drug-resistant and life-threatening fungal
strains like Candida auris."
Additional Details of the VT-1161 program presentations are as
follows:
Title: Investigational Agent VT-1161 Has a Low In Vitro
Potential for the Emergence of Stable Resistance in Candida spp.
Poster: 303 Date/Time: Sunday, June 4, 2017, 12:15 -
2:15 PM Location: Exhibit Hall D, Exhibit and Poster Hall,
Ernest N. Morial Convention Center Session: 349 - AAID09 -
Mycology: New Antifungal Agents II
Title: A Phase 1, Open-Label Study to Evaluate the Safety,
Tolerability and Pharmacokinetics of Multiple Oral Doses of VT-1161 in
Healthy Japanese and Western Subjects
Poster: 310 Date/Time: Sunday, June 4, 2017, 12:30 -
2:30 PM Location: Exhibit Hall D, Exhibit and Poster Hall,
Ernest N. Morial Convention Center Session: 349 - AAID09 -
Mycology: New Antifungal Agents II
Title: Oral VT-1161 is Highly Effective and Safe in Patients with
Recurrent Vulvovaginal Candidiasis- Results of REVIVE, a Multicenter
Phase 2b Study
Poster: AAID LB21 Date/Time: Sunday, June 4, 2017,
12:30 - 2:30 PM Location: Exhibit Hall D, Exhibit and Poster
Hall, Ernest N. Morial Convention Center Session: 334a -
SUNDAY (News - Alert) - AAID Late Breakers
Additional details of the VT-1598 program presentations are as
follows:
Title: The Novel Fungal Cyp51 Inhibitor VT-1598 Demonstrates
Potent In Vitro Activity Against Canida and Cryptococcus
Species
Poster: 237 Date/Time: Saturday, June 3, 12:15
- 2:15 PM (Note: designated as an oral poster and will be presented at
1:15 PM.) Oral Session: 240 - Design Evaluation and Novel
Combinations Involving New Antimicrobials, 1:15 - 1:25 PM Location:
Exhibit Hall D, Exhibit and Poster Hall, Ernest N. Morial Convention
Center Session: 195 - AAID09 - Mycology: New Antifungal
Agents I
Title: The Novel Fungal Cyp51 Inhibitor VT-1598 Demonstrates
Potent In Vitro Activity Against Endemic Fungi, Aspergillus,
and Rhizopus
Poster: 232 Date/Time: Saturday, June 3, 12:15
- 2:15 PM Location: Exhibit Hall D, Exhibit and Poster Hall,
Ernest N. Morial Convention Center Session: 195 - AAID09 -
Mycology: New Antifungal Agents I
Title: The Novel Fungal CYP51 Inhibitor VT-1598 Displays
Fungicidal Activity In Vivo
Poster: 302 Date/Time: Sunday, June 4, 12:15 -
2:15 PM Location: Exhibit Hall D, Exhibit and Poster Hall,
Ernest N. Morial Convention Center Session: 349 - AAID09 -
Mycology: New Antifungal Agents II
Title: VT-1598 is Efficacious in a Murine Model of Respiratory
Coccidioidomycosis
Poster: 305 Date/Time: Sunday, June 4, 12:15 - 2:15 PM Location:
Exhibit Hall D, Exhibit and Poster Hall, Ernest N. Morial Convention
Center Session: 349 - AAID09 - Mycology: New Antifungal
Agents II
Title: In Vitro Activity of a Novel CYP51 Inhibitor,
VT-1598, Against Clinical Isolates of Candida auris
Poster: 304 Date/Time: Sunday, June 4, 12:15 -
2:15 PM Location: Exhibit Hall D, Exhibit and Poster Hall,
Ernest N. Morial Convention Center Session: 349 - AAID09 -
Mycology: New Antifungal Agents II
About VT-1161 VT-1161 is a potent and selective,
orally-administered inhibitor of fungal CYP51 which recently
successfully completed Phase 2b clinical trials for the treatment of
onychomycosis, or fungal nail infection, and recurrent vulvovaginal
candidiasis (RVVC), a common and difficult to treat infection in women.
VT-1161 blocks the production of ergosterol, an essential component of
the fungal cell membrane. In preclinical studies, VT-1161 has
demonstrated broad-spectrum activity against both dermatophytes and Candida
species, including those species that cause onychomycosis and RVVC.
Given the clinical and preclinical profile of VT-1161, Viamet believes
that it may avoid the side effects that limit the use of current oral
antifungal therapies, such as liver toxicity and drug-drug interactions.
The U.S. Food and Drug Administration (FDA) has granted Qualified
Infectious Disease Product (QIDP) and Fast Track designations to VT-1161
for the treatment of RVVC.
About VT-1598 VT-1598 is an orally available inhibitor of
fungal CYP51 that has demonstrated high potency against a broad range of
fungal pathogens, including common molds and yeasts. VT-1598 is also
potent against a fungal class referred to as endemic fungi, which
includes Coccidioides, Histoplasma and Blastomyces species.
VT-1598 blocks the production of ergosterol, an essential component of
the fungal cell membrane. Viamet is developing VT-1598 for the treatment
of serious and life-threatening invasive fungal infections. Given the
preclinical profile of VT-1598, Viamet believes that it may avoid the
side effects that limit the use of current oral antifungal therapies,
such as liver toxicity and drug-drug interactions. The U.S. Food and
Drug Administration (FDA) has granted Qualified Infectious Disease
Product (QIDP) and orphan drug designation to VT-1598
for the treatment of Valley Fever.
About Viamet (www.viamet.com) Viamet
discovers and develops breakthrough therapies based on our leadership in
metalloenzyme chemistry and biology. Our clinical portfolio includes
novel agents to treat both chronic and life threatening fungal
infections. We also leverage our metalloenzyme expertise in other
therapeutic areas including oncology and orphan diseases. Focusing on
the needs of patients and clinicians, we design our drug candidates to
achieve superior efficacy and safety profiles compared to currently
marketed drugs.
This press release includes forward-looking statements. Actual
results may vary materially from these statements. There are many
important risks affecting Viamet's business, including that clinical
trials may not be commenced, or if commenced, may not be successful,
regulatory approvals may not be obtained and approved products, if any,
may not achieve commercial success. The Viamet group of companies
includes Viamet Pharmaceuticals Holdings, LLC and its operating
subsidiaries, Viamet Pharmaceuticals, Inc., VPS-2, Inc., VPS-3, Inc. and
Viamet Pharmaceuticals (Bermuda), Ltd. The Viamet group of companies are
based in the Research Triangle Park region of North Carolina, USA and
Hamilton, Bermuda.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170517005267/en/
[ Back To TMCnet.com's Homepage ]
|